Study Unveils Botox Ineffective In Case Of Headaches and Periodic Migraine

.

Study Unveils Botox Ineffective In Case Of Headaches and Periodic Migraine

As per recent findings, it has been suggested that the recommendation of botox for repetitive and periodic type of migraine and chronic tension type headaches, would be of no use, as the drug has not proved to be influential in such cases.

The drug was approved by the U. S. Food and Drug Administration (FDA) to be prescribed in cases of chronic migraines and no doubts it has been utilized, since a long time to reduce the sufferings in such cases, but it has failed for other similar conditions.

In order to acknowledge the effects of the drug, a team of researchers conducted a review, which analyzed the way Botox worked, in order to reduce the effect of migraines, tension or chronic daily headaches in adult patients.

Dr. Jeffrey L. Jackson of the Medical College of Wisconsin, Milwaukee, and his colleagues, who carried out the review, stated that their review categorized headaches into four categories: episodic (less than 15 per month), chronic (15 or more a month), and episodic or chronic daily or tension headaches.

Further, almost 27 random placebo trials were conducted on 5,300 patients that participated. The findings of the trials suggested that Botox was capable of reducing the amount of headaches per month in the cases, where the patients suffered from chronic daily headaches and chronic migraine headaches. However, other part of the story revealed that the drug failed to show any effects in case of patients who suffered from episodic migraines or chronic tension-type headaches.

The researchers said, "On average, patients who had chronic migraines and chronic daily headaches suffered two less headaches per month. The FDA approved injections reduced chronic headaches by about 10 percent".

However, the doctors who prescribe the drug state that it has shown significant results.


Latest News

Rise in Russian Arms Sales In spite of a Drop Globally
PetSmart Sells itself with an $8.3Billion Deal
Falling Oil Prices Result in a Drop in Stocks
Shares of Amaya Fall Due to Probe Conducted by Securities Regulators
Americans Consumers Display Confidence In the Market with Gain in Sales
It’s Time to Hurry Up to Enrol in the First Phase of Affordable Care Act Health
After Merger with Alliance Boots,	Walgreen CEO will Retire
Falling Fuel Prices Lift Airline Profits But No Respite in Fares Expected
Citigroup to Pay Likely $2.7B as Legal Charge
Michael Jeffries Retires as the CEO of Abercrombie & Fitch
Deutsche Bank in Trouble Again in the U.S. for Alleged Tax Scheme
Popular Demand Brings French Toast Crunch Back on the Shelves